Core Viewpoint - AbbVie is expanding its presence in the obesity treatment market by in-licensing GUB014295, a long-acting amylin analog, from Gubra, with a total potential deal value of $2.225 billion [1][2][3] Industry Overview - The obesity market is projected to reach $100 billion by 2030, with current dominance by GLP-1 drugs from Eli Lilly and Novo Nordisk [3] - Major pharmaceutical companies, including Merck, Pfizer, Amgen, and AstraZeneca, are actively pursuing opportunities in the obesity space through in-house development or licensing deals [3] AbbVie's Product Performance - AbbVie has successfully launched Skyrizi and Rinvoq, generating combined sales of $17.7 billion in 2024, particularly excelling in the inflammatory bowel disease market [5][6] - The company anticipates combined sales of Skyrizi and Rinvoq to exceed $31 billion by 2027, driven by market growth and new indications [7] Pipeline and Acquisitions - AbbVie has a robust pipeline with several early/mid-stage candidates and expects multiple regulatory submissions and approvals in the next 12 months [8][9] - The company has been active in acquisitions, signing over 20 early-stage deals in 2024 to enhance its pipeline in immunology, oncology, and neuroscience [11][12] Sales Trends and Challenges - AbbVie is experiencing declining sales from Humira due to biosimilar competition, with a sharper decline expected in 2025 [13] - The aesthetics portfolio, including Juvederm fillers, has also seen a decline, with a 14.6% drop in sales in 2024 [14][15] Stock Performance and Valuation - AbbVie stock has outperformed the industry with a 14.8% increase over the past year [16][18] - The stock trades at a price/earnings ratio of 16.52, slightly below the industry average of 17.80, but higher than many large drugmakers [19][20] Earnings Estimates - The Zacks Consensus Estimate for AbbVie's 2025 earnings has increased from $12.24 to $12.29 per share, indicating positive sentiment [22]

A version of this article first appeared in CNBC's Healthy Returns newsletter, which brings the latest health-care news straight to your inbox. Subscribe here to receive future editions.The booming weight loss drug market has gained a new potential competitor. AbbVie said on Monday that it will pay up to $2.2 billion to develop Danish drugmaker Gubra's experimental obesity drug, marking its late foray into the segment. Under the terms of the deal, the pharmaceutical giant will pay Gubra $350 million upfront ...

NORTH CHICAGO, Ill., March 4, 2025 /PRNewswire/ -- AbbVie (NYSE: ABBV) will participate at the Leerink Partners Global Healthcare Conference on Tuesday, March 11, 2025. Management will participate in a fireside chat at 7:40 a.m. Central time.A live audio webcast of the presentation will be accessible through AbbVie's Investor Relations website at investors.abbvie.com. An archived edition of the session will be available later that day.About AbbVieAbbVie's mission is to discover and deliver innovative medici ...

On Monday, AbbVie Inc ABBV and Gubra A/S announced a license agreement to develop GUB014295, a long-acting amylin analog for obesity. GUB014295 is currently in a Phase 1 clinical trial.“Our partnership with Gubra marks our entry into the obesity field, offering a compelling opportunity based on the potential to address patient needs while also fostering long-term growth for our company,” said Robert Michael, CEO of AbbVie.Also Read: Is Big Pharma About To Win? Goldman Sachs Weighs In On 340B And Medicaid Sh ...

Core Insights - AbbVie and Gubra A/S have entered into a license agreement to develop GUB014295, a long-acting amylin analog aimed at treating obesity, marking AbbVie's entry into the obesity treatment market [1][2][3] - GUB014295 is currently in Phase 1 clinical trials and is designed to activate amylin and calcitonin receptors, which may help suppress appetite and reduce food intake [2][3] - The agreement includes an upfront payment of $350 million to Gubra, with potential milestone payments totaling up to $1.875 billion, along with tiered royalties on global net sales [3] Company Overview - AbbVie is focused on innovative medicines addressing significant health issues, with a mission to transform patient care in areas of unmet need [2][8] - Gubra specializes in preclinical contract research services and peptide-based drug discovery, particularly in metabolic and fibrotic diseases, and reported revenue of DKK 266 million in 2024 [9] Clinical Development - The Phase 1 clinical trial of GUB014295 consists of two parts: Part 1 has been completed, while Part 2 is ongoing, involving a randomized, placebo-controlled design [6][7]

Core Viewpoint - The upcoming January reading of the Personal Consumption Expenditure (PCE) index is expected to indicate persistent inflation, prompting investors to consider sectors that can benefit from inflation rather than fleeing the stock market entirely [1][2]. Inflation Overview - The PCE index is anticipated to confirm previous inflation readings from the Consumer Price Index (CPI) and Producer Price Index (PPI), suggesting inflation rates are likely to rise rather than approach the Federal Reserve's target [2]. - U.S. consumers now expect inflation to increase to 6% over the next 12 months, up from 5.2% [3]. Interest Rates Impact - Rising interest rates, implemented to combat inflation, have led to stock market volatility, particularly affecting technology stocks due to concerns over higher borrowing costs [3][4]. - There are indications that the Federal Reserve may need to raise rates again, delaying potential rate cuts [3]. Defensive Sectors to Watch - Defensive sectors are highlighted as potential investment opportunities, characterized by companies that provide essential products and services regardless of economic conditions [5][6]. - These sectors typically feature strong balance sheets and pricing power, allowing for solid earnings growth and dividends [5][6]. Biopharmaceuticals - The biopharmaceutical sector is divided into small-cap companies with high-risk profiles and blue-chip stocks like AbbVie and Merck, which offer value and growth potential due to their established drug portfolios and strong pipelines [7][9]. Consumer Staples - Consumer staples are expected to perform well in inflationary environments, with companies like PepsiCo and Mondelez showing pricing power and reliable dividends [11][12]. - Other notable companies in this sector include Procter & Gamble and Kimberly-Clark, which also exhibit similar attributes [13]. Utilities - Utility stocks are considered reliable investments due to their consistent demand, with NextEra Energy being a notable example [14][15]. Metals and Mining - Metals and mining stocks, particularly those related to gold and copper, are viewed as inflation hedges, with companies like Newmont and Freeport-McMoRan recommended for exposure to precious metals [16][17].

Core Viewpoint - AbbVie announced a positive opinion from the European Medicines Agency's Committee for Medicinal Products for Human Use (CHMP) recommending the approval of upadacitinib (RINVOQ®) for treating adult patients with giant cell arteritis (GCA), with a final decision expected in the first half of 2025 [1][2]. Group 1: Product Information - Upadacitinib (RINVOQ) is a selective and reversible JAK inhibitor being studied for various immune-mediated inflammatory diseases, including GCA [7]. - If approved, upadacitinib would be the first and only oral advanced therapy for adults with GCA [1]. - RINVOQ is already approved in the EU for several conditions, including rheumatoid arthritis, psoriatic arthritis, and ulcerative colitis [2][8][12]. Group 2: Clinical Trial Data - The positive opinion is based on the pivotal Phase 3 SELECT-GCA clinical trial, which evaluated the efficacy and safety of upadacitinib in adults aged 50 and older with GCA [2][5]. - The trial involved 428 patients and demonstrated that the primary endpoint of sustained remission and key secondary endpoints were met [5][6]. - The safety profile of upadacitinib during the trial was consistent with that observed in other approved indications [2][5]. Group 3: Disease Background - GCA is an inflammatory disease that can lead to severe outcomes such as blindness and stroke if untreated [2][4]. - It is the most common vasculitis affecting adults in Western countries, with the highest risk among white women over 50 years old [4].

Group 1 - The Dividend Kings have shown strong performance in January 2025, achieving an average total return of 2.04% [1] - The performance of the Dividend Kings is noteworthy compared to the SPDR S&P 500 Trust ETF [1] Group 2 - The article reflects the author's personal investment positions in several companies, indicating a long position in shares of ABBV, ADP, GWW, HRL, JNJ, LOW, PEP, and SPGI [2]

Group 1 - AbbVie will participate in the TD Cowen's 45th Annual Health Care Conference on March 5, 2025, with management engaging in a fireside chat at 8:10 a.m. Central time [1] - A live audio webcast of the presentation will be available on AbbVie's Investor Relations website, with an archived version accessible later that day [1] Group 2 - AbbVie's mission focuses on discovering and delivering innovative medicines and solutions to address serious health issues and future medical challenges [2] - The company aims to make a significant impact in key therapeutic areas including immunology, oncology, neuroscience, and eye care, along with products in the Allergan Aesthetics portfolio [2]

Group 1 - The article discusses the potential benefits of investing in various income alternatives such as REITs, mREITs, Preferreds, BDCs, MLPs, and ETFs [1] - It highlights the positive feedback from users, with 438 testimonials, most of which are rated 5 stars, indicating a strong level of satisfaction with the research provided [1] Group 2 - There is a mention of a hypothetical scenario where two individuals relocate to a distraction-free tropical island for five years, emphasizing the importance of focus and environment in decision-making [1]